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creativecommons.org/licenses/by-nc-nd/Abstract Background: The present study (VINGEM) is the first randomised trial comparing
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with
advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin.
Patients and methods: Patients with aUC, creatinine clearance 30e60 ml/min, performance
status 1 and no prior chemotherapy for metastatic disease were randomised to the experi-
mental arm (vinflunine 280 or 250 mg/m2 day 1, gemcitabine 1000 mg/m2 days 1 and 8, q21f Oncology-Pathology, Karolinska Institute, 171 77, Stockholm, Sweden. Fax: þ46 8 58701941.
e (K. Holmsten).
ncology, Capio St Göran Hospital, Stockholm, Sweden.
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
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gemcitabine;
Carboplatin/
gemcitabinedays) or the control arm (carboplatin AUC 4.5 day 1, gemcitabine 1000 mg/m2 days 1 and 8,
q21 days). Primary end-point was progression-free survival (PFS).
Results: Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30
CG). There was no significant difference in PFS between the treatment arms: median 6.2
months for VG versus 6.3 months for CG (hazard ratio [HR]: 0.75, 95% confidence interval
[CI]: 0.44e1.28; P Z 0.293). Median overall survival was 12.5 months for VG versus 10.6
months for CG. The overall response rate (ORR) was higher in the VG arm than in the
CG arm (63% versus 40%) but was not statistically significant in the intention-to-treat anal-
ysis. Furthermore, VG showed a high complete response (CR) rate, 22% versus 3% in CG.
In the per-protocol group, both ORR and CR were significantly higher for VG than for
CG. The most common adverse events (AEs) were fatigue, haematological toxicities, gastro-
intestinal disorders and nausea/vomiting. Common grade III/IV AEs were neutropenia (VG
62%, CG 43%), thrombocytopenia (VG 7%, CG 37%) and febrile neutropenia (VG 31%,
CG 7%).
Conclusions: The combination of VG did not improve PFS compared with standard treatment
with CG in patients unfit for cisplatin due to renal impairment. The response rate of VG in-
dicates, however, an active regimen and warrants further studies.
Clinicaltrials.gov number: NCT02665039.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the late 1980s, cisplatin-based chemotherapy has
been the standard treatment for locally advanced and
metastatic urothelial cancer (aUC) [1e3]. However, up to
50% of patients with aUC are ineligible, or ‘unfit’, for
cisplatin [4], either because of impaired renal function, low
performance status or co-morbidity.
Thus far, the European Organisation for Research
and Treatment of Cancer (EORTC) study 30986 repre-
sents the first and only reported randomised phase III
trial including patients ineligible for cisplatin and
comparing methotrexate, carboplatin and vinblastine
(M-CAVI) with carboplatin and gemcitabine (CG) [5,6].
This study showed no significant differences between the
treatment groups with regards to overall response rate
(ORR; 41% with CG versus 30% with M-CAVI) or
median overall survival (mOS; 9.3 versus 8.1 months),
although there was a significant difference in severe
acute toxicity in favour of CG. Based on this trial, CG is
recommended as one standard first-line treatment for
cisplatin-unfit patients with aUC [7,8].
Recently, immunotherapy with checkpoint inhibitors
(ICIs) has proven efficacy in first-line treatment for
cisplatin-unfit patients with aUC. Pembrolizumab [9]
and atezolizumab [10] show in single-arm phase II trials
an ORR of 24% and 23%, respectively, and the reported
mOS for atezolizumab was 15.9 months. The use of ICIs
is currently restricted to patients expressing high levels
of programmed death-ligand 1 (PD-L1), approximately
30% [11] of the patients [12,13].
In 2009, the European Medicines Agency (EMA)
approved the third-generation anti-microtubuleinhibitor vinflunine as second-line treatment after plat-
inum-based chemotherapy in patients with aUC,
improving mOS for vinflunine compared with best
supportive care in the eligible population (but not in the
intention-to-treat [ITT] population) [14]. Furthermore,
the efficacy of vinflunine in second-line treatment has
been confirmed in real-world studies [15]. Vinflunine
combinations, vinflunine and gemcitabine (VG) versus
vinflunine and carboplatin, were explored as first-line
treatment for cisplatin-unfit patients in the randomised
phase II trial JASINT1 [16], showing promising
response rates and survival (ORR 53% with confirmed
ORR 44% and mOS 14.0 months in the VG arm),
although the trial did not include a non-investigational
control arm.
Based on available data on vinflunine as second-line
treatment in patients with aUC and the potential benefit
of vinflunine combination therapy as first-line treat-
ment, we explored the efficacy of VG versus standard
chemotherapy with CG in the randomised phase II
VINGEM trial in patients with aUC unfit for cisplatin
due to renal impairment.
2. Patients and methods
2.1. Study design
The randomised multicentre phase II trial VINGEM
was conducted at 11 centres associated with the Nordic
Urothelial Cancer Oncology Group (NUCOG) in
Denmark, Finland and Sweden. The study protocol was
approved by the EMA and by the national medicine
agencies and independent ethics committees in each of
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accordance with the Declaration of Helsinki and Good
Clinical Practice, as well as with local laws and regula-
tions. All patients provided written informed consent.
2.2. Patients
Eligible patients had histologically confirmed transi-
tional cell carcinoma of the urothelial tract with evalu-
able locally advanced (T4bN0M0) or metastatic disease
and impaired glomerular filtration rate (GFR) of
30e60 ml/min measured by Iohexol or Cr-ethylene
diamine tetra-acetic acid (EDTA) clearance and Eastern
Cooperative Oncology Group (ECOG) performance
status (PS)  1. Prior chemotherapy was not allowed,
except for perioperative platinum-containing chemo-
therapy given 6 months before disease relapse. The
main exclusion criteria were any history of serious
concurrent illness or uncontrolled medical condition,
impaired bone marrow or liver function and other ma-
lignancies. Complete inclusion and exclusion criteria are
given in the protocol (Supplementary Appendix).
2.3. Procedures
Patients were randomised 1:1 and stratified for ECOG
PS 0 versus 1 and presence or absence of visceral me-
tastases. Vinflunine was administered at 250 mg/m2
(age > 80 years and/or GFR 30e40 ml/min) or 280 mg/
m2 (GFR 41e60 ml/min) on day 1 and gemcitabine at
1000 mg/m2 on days 1 and 8, q21 days, or carboplatin
AUC 4.5 was given on day 1 and 1000 mg/m2 of gem-
citabine on days 1 and 8, q21 days. Treatment continued
until disease progression, unacceptable toxicity or pa-
tient withdrawal of consent.
Dose reduction and dose delay were permitted ac-
cording to the protocol. Granulocyte colony-stimulating
factor (G-CSF) was allowed when the per-protocol
recommended dose modifications were insufficient.
2.4. Outcomes
The primary end-point was progression-free survival
(PFS), defined as the time from randomisation to
radiological disease progression or death. The secondary
end-points were ORR, disease control rate (DCR), OS,
toxicity and health-related quality of life (HRQoL).
Radiological assessment was performed at baseline and
every 6 weeks until progression by computer tomogra-
phy or magnetic resonance imaging as per Response
Evaluation Criteria in Solid Tumours (RECIST),
version 1.1. Objective responses were confirmed at the
next scheduled radiological assessment or at an addi-
tional evaluation after 28 days if the treatment was
terminated for any reason other than progression.AEs were graded after every treatment cycle in
accordance with the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE),
version 4.0. HRQoL was assessed before randomisation,
every 6 weeks during treatment, and at discontinuation of
treatment using the 30-item EORTC Quality of Life Core
Questionnaire (QLQ-C30, version 3.0) [17].
2.5. Statistical analysis
The study was designed as a randomised phase II
screening trial, with PFS as the primary end-point [18].
The trial was initially intended to detect an increase in
the median PFS from 5 to 7.5 months, requiring inclu-
sion of 120 patients. In April 2016, owing to slow
accrual rate, an amendment was approved to decrease
the required number of patients to 60 to enable detec-
tion of an increase in median PFS from 5 to 9 months
(with a Z 10% and b Z 20%).
PFS was compared between the treatment arms using
the log-rank test at a significance level of 5%. Hazard
ratios (HRs) were calculated using a Cox proportional-
hazards model. The Kaplan-Meier technique was
applied to estimate time-related end-points. Efficacy was
evaluated according to the ITT principle comprising all
randomised patients and in an additional analysis in the
per-protocol population, i.e. excluding those patients
who completed less than one treatment cycle. ORR and
DCR were tested by the Fisher exact test. Descriptive
statistics were used to assess safety for all patients who
received at least one dose of study treatment. All items
in the EORTC QLQ-C30 questionnaire were linearly
transformed to functioning or symptom scales ranging
from 0 to 100 according to the scoring manual [19]. The
differences in HRQoL were analysed at baseline and
after two treatment cycles, using linear regression
models and scored with 99% confidence intervals (CIs)
and with statistical significance set at p  0.01. Statis-
tical analyses were performed using STATA software,
version 15 (StataCorp LLC, Texas, USA).
3. Results
3.1. Patients
Between April 2014 and February 2018, 62 patients were
randomised to receive treatment with VG (n Z 32) or
CG (n Z 30) (Fig. 1). Baseline characteristics were well
balanced between the two arms (Table 1). At the cut-off
time for data analysis (31 September 2018), no patients
were on study treatment and 57 patients had progressed
in their disease or died. The median follow-up duration
was 21 months (range, 6e41 months) with 44 deaths. All
patients were included in the ITT analysis (n Z 62).
Three patients in the VG arm were excluded in the per-
Patients randomized (n = 62) 
Allocated to VG (n = 32) 
•  Received at least one cycle    
of treatment (n = 29) 
•  Ineligible (n = 3)*
Allocated to CG (n = 30) 
•  Received at least one cycle    
of treatment (n = 30)
Discontinued treatment (n = 30)       
•  Progressive disease (n = 5)  
•  Toxicity (n = 16)                    
•  Death (n = 1)               
•  Patient’s choice  (n = 1) 
•  Other (n = 7)†
•  Did not start treatment (n = 2) 
Discontinued treatment (n = 30)  
•  Progressive disease (n = 14)     
•  Toxicity (n = 11)          
•  Patient’s choice (n = 1)         
•  Protocol violation (n = 2)         
•  Other (n = 2)†
Analysed for efficacy and response: 
•  Intention-to-treat (n = 32) 
•  Per protocol (n = 29)*
Evaluable for safety (n = 29)*
Evaluable for HRQoL (n = 32) 
Analysed for efficacy and response: 
•  Intention-to-treat (n = 30) 
•  Per protocol (n = 30) 
Evaluable for safety (n = 30) 
Evaluable for HRQoL (n = 30) 
Fig. 1. CONSORT diagram. *Two patients were excluded because of adverse events before onset of treatment, one patient withdrew
because of immediate local infusion site reaction upon the first exposure of vinflunine. yInvestigator’s decision due to local procedures after
six cycles (six patients), complete response and no improvement of HRQoL (one patient), deterioration of performance status (one pa-
tient), stroke (one patient). VG, vinflunine and gemcitabine; CG, carboplatin and gemcitabine; HRQoL, health-related quality of life.
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of AEs before onset of treatment (stroke and ileus) and
one was excluded because of immediate local infusion
site reaction upon the first exposure of vinflunine
(withdrawn from further study treatment).3.2. Treatment
The median number of treatment cycles was 4.0 in the VG
arm (range, 0e14) and 5.5 in the CG arm (range, 2e10)
(Supplementary Table S1). In the VG arm, three patients
received no treatment and five received only one cycle.
Three of these eight early treatment terminations were
deemed to be treatment related: infusion site reaction of
vinflunine leading to treatment interruption at cycle 1,
death due to febrile neutropenia, and infection after the
first cycle. In the control arm, all patients received at least
two cycles of treatment. The most common reason for
treatment discontinuation was toxicity in the VG arm
(50%) and progressive disease in the CG arm (47%). Any
event of dose reduction was performed in 83% and 90% of
patients in the VG and CG arm, respectively. Dose
reductionwasmore often due to haematological toxicity in
the CG arm but more frequently due to infection and
constipation in theVGarm.Dose delay occurred in 48%of
the patients in the VG arm and 73% of the patients in the
CG arm (Supplementary Table S2).3.3. Efficacy
In the ITT population, there was no significant differ-
ence between the VG and CG arms for the primary end-
point PFS (HR Z 0.75, 95% CI: 0.44e1.28; p Z 0.29)
(Fig. 2A): 6.2 months for VG versus 6.3 months for CG.
In addition, OS was similar between the two groups:
12.5 months for VG versus 10.7 months for CG
(HR Z 1.08, 95% CI: 0.60e1.93; p Z 0.81) (Fig. 2B).
Furthermore, in the per-protocol population, there were
no significant differences in PFS or OS between the
treatment arms as shown in Table 2.
TheORRwas higher in theVGarm than in theCGarm
(63% versus 40%, respectively) but was not statistically
significant in the ITT analysis (Table 2). Furthermore, the
VG arm showed a high complete response (CR) rate, i.e.
22% versus 3% in the CG arm. In the per-protocol group,
both ORR and CR were significantly higher for VG than
for CG (p Z 0.037 and p Z 0.026, respectively). The me-
dian duration of response in the ITT population was 7.8
months in theVGarm and 8.4 in the CGarm (Fig. 3B). All
responses were confirmed except in two patients with
partial response (PR).
In the VG arm, the primary tumour was a target
lesion in three patients; all responded to treatment (one
with CR and two with PR). Moreover, eight patients
had the primary tumour registered as non-target lesion
(three in VG and five in the CG arm). With respect to
Table 1
Baseline clinical characteristics of the intention-to-treat population.
Characteristic Vinflunine
/gemcitabine
(n Z 32)
Carboplatin
/gemcitabine
(n Z 30)
Sex
Male 24 (75) 20 (67)
Female 8 (25) 10 (33)
Median age, years (range) 71 (50e84) 74 (43e82)
ECOG performance status
0 17 (53) 12 (40)
1 15 (47) 18 (60)
Median creatinine clearance, ml/
min (range) 43 (30e55) 47 (32e57)
30e40 ml/min 8 (25) 5 (17)
40e60 ml/min 24 (75) 25 (83)
Primary tumour
Bladder 20 (63) 22 (73)
Renal pelvis 9 (28) 6 (20)
Ureter 2 (6) 2 (7)
Unknown locationa 1 (3) 0
Disease extent
Advanced locoregionalb 1 (3) 2 (7)
Metastatic 30 (94) 28 (93)
Unknown extenta 1 (3) 0
Visceral metastases 18 (56) 18 (60)
Only non-visceral metastases 14 (44) 12 (40)
Metastatic site
Locoregional recurrence 8 (25) 6 (20)
Regional lymph nodes 17 (53) 13 (43)
Distant lymph nodes 14 (44) 12 (40)
Lung 11 (34) 9 (30)
Liver 5 (16) 7 (23)
Bone 1 (3) 9 (30)
Other 5 (16) 3 (10)
Unknown sitesa 1 (3) 0
Prior locoregional curative treatments
Cystectomy/nephrectomy 21 (66) 20 (67)
Radiotherapy 0 2 (7)
Prior neoadjuvant chemotherapy 1 (3) 5 (17)
Prior adjuvant chemotherapy 0 1 (3)
Median time since perioperative
chemotherapy, months
7.7 18.5
ECOG, Eastern Cooperative Oncology Group.
Data are n (%), except where noted.
a Baseline data missing because of stroke before onset of treatment
(one patient).
b Primary T4bN0M0 (one patient), locoregional recurrence only
(two patients).
Fig. 2. Efficacy in the intention-to-treat population. (A)
Progression-free survival. (B) Overall survival. VG, vinflunine and
gemcitabine; CG, carboplatin and gemcitabine.
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versus bladder tumours), no clear differences in efficacy
were observed (Supplementary Table S4).
3.4. Safety and health-related quality of life
Overall, 59 patients received at least one treatment cycle
and were evaluated for safety, in accordance with the
protocol. AEs are summarised in Table 3. The most
common AEs were haematological toxicities, fatigue,
gastrointestinal disorders and nausea/vomiting.
The most common grade III/IV haematological AEs
were neutropenia (62% in VG and 43% in CG) and
thrombocytopenia (7% in VG and 37% in CG). Febrileneutropenia occurred more often in the VG arm (31%)
than in the CG arm (7%). One patient in the VG group
died due to infection secondary to treatment-induced
febrile neutropenia (grade V). Considering all patients,
the majority (90%) of the non-haematological AEs were
grade I/II. Renal toxicity was uncommon, with 14% in
the VG arm and 7% in the CG group, and no grade III/
IV.
HRQoL was assessable in 90% of the patients at
baseline and in 58% of the patients after two treatment
cycles. There were no statistical differences between the
VG and CG arms in any of the HRQoL variables at
baseline or after two cycles (Supplementary Table S3).
Moderate clinical differences (10e19 points) favouring
the control arm were found for physical functioning,
role functioning, fatigue and diarrhoea. Small clinical
differences (5e9 points) in the same direction were
Table 2
Efficacy variables in the intention-to-treat and per-protocol populations.
Efficacy variable Intention-to-treat Per-protocola
Vinflunine
/gemcitabine
n Z 32
Carboplatin
/gemcitabine
n Z 30
HR and/or p-value Vinflunine
/gemcitabine
n Z 29
Carboplatin
/gemcitabine
n Z 30
HR and/or p-value
Median PFS,
months (95% CI)
6.2 (4.4e8.3) 6.3 (4.2e7.8) HR 0.75 (0.44e1.28)
p Z 0.293
6.6 (5.0e8.2) 6.3 (4.2e7.8) HR 0.71 (0.41e1.22)
p Z 0.210
Median OS,
months (95% CI)
12.5 (8.4e15.8) 10.7 (7.4e17.0) HR 1.08 (0.60e1.93)
p Z 0.810
14.3 (9.2e16.0) 10.6 (7.4e17.0) HR 0.95 (0.52e1.75)
p Z 0.879
Response
Complete response 7 (22) 1 (3) p Z 0.054 7 (24) 1 (3) p Z 0.026a
Partial response 13b (41) 11 (37) p Z 0.799 13b (45) 11 (37) p Z 0.601
Stable disease 3 (9) 12 (40) p Z 0.007a 2 (7) 12 (40) p Z 0.005a
Progressive disease 5 (16) 6 (20) p Z 0.746 5 (17) 6 (20) p Z 1.000
Not evaluable 4 (13) 0 p Z 0.114 2 (7) 0 p Z 0.237
Overall response rate 20b (63) 12 (40) p Z 0.126 20b (69) 12 (40) p Z 0.037a
Disease control rate 23b (72) 24 (80) p Z 0.558 22b (76) 24 (80) p Z 0.761
PFS, progression-free survival; CI, confidence interval; HR, hazard ratio; OS, overall survival; AE, adverse event.
HR is calculated with the log-rank test, and p-value, with the Fisher exact test.
Data are represented as n (%), except where noted.
*Statistically significant, p < 0.05.
a Two patients were excluded because of AE before onset of treatment; one patient withdrawn because of infusion site reaction at first cycle.
b Two patients with partial response did not have confirmed responses.
K. Holmsten et al. / European Journal of Cancer 127 (2020) 173e182178found between the treatment groups for global health
status, social functioning, nausea and vomiting and
constipation.4. Discussion
The VINGEM trial is the first randomised study to
compare VG treatment with standard CG as first-line
therapy for patients with aUC ineligible for cisplatin due
to renal impairment. After the present trial was
designed, immunotherapy was approved as first-line
treatment for cisplatin-unfit patients with aUC.
Although immunotherapy has shown impressive and
durable responses, the ORR is less than 25% for pem-
brolizumab and atezolizumab [9,10]. Recently, the EMA
and Food and Drug Administration restricted the indi-
cation for first-line use of both of these checkpoint in-
hibitors to patients with high PD-L1 expression; for the
non-high PD-L1 expressing population, approximately
70% of the patients [11], chemotherapy with CG remains
recommended standard treatment, and further devel-
opment of more efficacious regimens represents an
unmet medical need [20].
The present trial included patients with favourable
performance status (1) and with renal impairment as
the only criterion necessary to be considered ineligible
for cisplatin treatment. The median PFS and OS
observed in the VG arm were not significantly improved
compared with the control arm, although they were
similar to what was shown in the JASINT1 trial [16],
which applied the same criteria as used in the present
study to define cisplatin ineligibility. In our study, there
were eight early treatment terminations in the VG armbut none in the control arm, although only three of these
eight terminations were deemed to be treatment related.
Thus, eight of 32 patients in the VG arm received only
0 or 1 cycle of treatment, which may have affected the
survival outcomes and interpretation of the overall ef-
ficacy in the ITT population.
Although ORR was not the primary end-point in this
study, the high response rate of 63% observed in the VG
arm, including 22% CR rate, was notable. This response
rate exceeds the numbers reported for other chemo-
therapy regimens in unfit patients, e.g. the phase III trial
CG vs M-CAVI [5] (including the subgroup treated with
CG unfit to cisplatin only due to impaired renal func-
tion, ORR 47%, CR 6%), the JASINT1 trial [16] and
vinflunine in second-line treatment [14,15]. The response
rate in our trial is comparable with the best response
data reported for cisplatin-based chemotherapy in aUC
[3,21,22]. In the per-protocol population, ORR and CR
rate differed statistically significantly between the
treatment arms in favour of VG. Interestingly, there
were also apparent inter-individual> variations in effi-
cacy within the VG arm. As demonstrated in Fig. 3A,
several patients showed durable PR and CR, whereas
other subjects seemed de novo resistant.
Overall, side-effects in both treatment arms were
manageable. However, AEs were more frequently re-
ported in the VG arm, although this was not reflected as
any detectable significant differences in HRQoL. Hae-
matological toxicity was comparable with what has
previously been reported for VG [16] and CG [5].
However, grade III/IV neutropenia for VG was more
common in the present study than in the JASINT1 trial
[16] (62% versus 38%) but was similar to previously re-
ported incidences for CG [5] and for vinflunine as
Fig. 3. (A) Percentage change in sum of target lesion diameters from baseline over time. Patients with only non-target lesions are excluded.
The diagram illustrates, according to RECIST, version 1.1, progression at 20% (upper dotted line) and response at 30% (lower dotted line).
(B) Time to response and duration of response in patients with objective response according to RECIST, version 1.1. Bars indicate the
duration of response at the time of data cut-off. RECIST, Response Evaluation Criteria in Solid Tumours.
K. Holmsten et al. / European Journal of Cancer 127 (2020) 173e182 179monotherapy in the post-platinum setting [14]. More-
over, a high rate of infection and febrile neutropenia was
observed in the VG arm, including one febrile neu-
tropenia-related death. In the JASINT1 trial, the start
dose for gemcitabine was 750 mg/m2, with possibility to
escalate to 1000 mg/m2 in cycle 2. Nonetheless, the dose
was increased for only 52% of the patients, and thus, thelower incidence of neutropenia and febrile neutropenia
observed in the JASINT1 trial may be at least partly
explained by administration of a lower median dose of
gemcitabine. In view of the observed toxicity in the
present trial, in particular, the high incidence of neu-
tropenia and associated febrile neutropenia, adjusted
doses and treatment schedules or the addition of G-CSF
Table 3
Adverse events (AEs)a.
Adverse event Vinflunine/gemcitabine, n Z 29b Carboplatin/gemcitabine, n Z 30
All grades Grade III/IV All grades Grade III/IV
Haematological AE (predefined)
Anaemia 17 (59) 4 (14) 20 (67) 8 (27)
Neutropenia 18 (62) 18 (62) 18 (60) 13 (43)
Febrile neutropenia e 9c(31) e 2 (7)
Thrombocytopenia 11 (38) 2 (7) 14 (47) 11 (37)
Thrombocytopenia with active bleeding 1 (3) 0 3 (10) 1 (3)
Non-haematological AE (predefined)
Constipation 16 (55) 1 (3) 6 (20) 0
Abdominal pain 9 (31) 1 (3) 3 (10) 0
Fatigue 25 (86) 1 (3) 23 (77) 3 (10)
Nausea 13 (45) 1 (3) 11 (37) 2 (7)
Vomiting 9 (31) 0 2 (7) 0
Stomatitis/mucositis 14 (48) 1 (3) 8 (27) 0
Musculoskeletal disorders, pain 7 (24) 2 (7) 9 (30) 2 (7)
Infusion site reactions 7 (24) 0 3 (10) 0
Renal toxicity 4 (14) 0 2 (7) 0
Peripheral neuropathy 5 (17) 0 6 (20) 0
Alopecia 15 (52) e 3 (10) e
Dehydration 2 (7) 2 (7) 0 0
Fever 7 (24) 1 (3) 3 (10) 0
Infection 9 (31) 5 (17) 5 (17) 2 (7)
Other AEs, (not predefined)d
Anorexia/weight loss 11 (38) 0 7 (23) 0
Diarrhoea 7 (24) 0 4 (13) 1 (3)
Dyspnoea 3 (10) 0 1 (3) 0
Oedema limbs 3 (10) 0 1 (3) 0
Skin reactions (including pruritus, rash) 4 (14) 0 4 (13) 1 (3)
Data are represented as n (%), except where noted.
a Possibly treatment-related AEs in at least one arm.
b Two patients were excluded because of AE before onset of treatment; one patient withdrawn because of infusion site reaction at first cycle.
c One patient died because of febrile neutropenia, grade V.
d Possibly related AEs in at least one arm in 10% of patients.
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The treatment landscape of aUC is rapidly expand-
ing, including several ICIs [23], targeted therapies such
as inhibitors of fibroblast growth factor receptor family
(FGFR) [24] and antibody-drug conjugates targeting
nectin-4 [25]. In this era of several conceptually different
treatment strategies, there is an unmet need of robust
predictive biomarkers to optimise patient selection and
treatment sequence. PD-L1 expression has been sug-
gested as a predictive biomarker for treatment with
ICIs, but is controversial due to different analytical
methods and its significance is still unclear in both first-
and second-line treatment in aUC [23]. Furthermore,
besides being a potential predictive biomarker, PD-L1
expression may also be a prognostic marker for pa-
tients treated with ICIs or chemotherapy [23,26,27].
Hence, it would be of interest to evaluate the PD-L1
expression in relation to the outcomes of VG as well.
Since ICIs appear to be non-efficient in cisplatin-ineli-
gible aUC-patients with low PD-L1 expression, effica-
cious treatment options in this population remain an
unmet need. Although the toxicity profile must be taken
into consideration, VG may be an effective and feasiblealternative to CG in patients with good performance
status and preserved bone marrow function.
This study has several limitations. The trial was
initially planned for 120 patients but was downsized due
to slow accrual rate, which reduces the statistical power
and the probability of demonstrating significant differ-
ences between the treatment arms. Furthermore, there
was an imbalance between the treatment arms consid-
ering the number of patients that had received periop-
erative chemotherapy, which may influence sensitivity to
study treatment and the efficacy outcome. In addition, a
randomised phase II screening trial design requires
verification of positive findings in a subsequent phase III
trial.5. Conclusions
In this trial, first-line treatment with VG did not
improve PFS compared with standard carboplatin-
based treatment in patients with aUC considered
cisplatin-unfit due to renal impairment. However, the
experimental VG arm did show notable activity, with an
ORR and a CR rate comparable with the best response
K. Holmsten et al. / European Journal of Cancer 127 (2020) 173e182 181rates previously reported for any systemic therapy in
aUC. Moreover, the VG regimen was generally tolerable
and had an expected side-effect profile, albeit with a
high frequency of neutropenia and febrile neutropenia.
Future studies are warranted to identify biomarkers
specific for the VG combination and to address inter-
individual differences in efficacy in the context of mo-
lecular taxonomy and PD-L1 expression. Furthermore,
it may also be of interest to explore the VG regimen in
the neoadjuvant setting for patients with impaired renal
function or as backbone in combination with immuno-
therapy or targeted drugs.
Conflict of interest statement
K.H. declares receiving speaker honoraria from
Roche AB and Ipsen. L.S.M. has served the role of a
consultant, has been a member of the advisory board for
MSD and reports receiving reimbursement for travel,
accommodations and meeting expenses from MSD,
Roche, Pfizer, BMS, Janssen and Astellas. H.P. has
received research grants from MSD and Roche, has
been a member of the advisory board in MSD Denmark
and has received speaker honoraria for BMS. A.U. has
received research grants from Swedish Cancer Society,
Stockholm County Council, the Cancer Society in
Stockholm, King Gustaf V Jubilee Fund, Sanofi-
Aventis, Bayer and Pierre Fabre; reports receiving
speaker honoraria and has been a member of the advi-
sory board for Pierre Fabre, Amgen, Roche, Pfizer,
Janssen-Cilag and MSD. All remaining authors have
declared no conflicts of interest.
Funding
This trial was an academic study supported by grants
from the Swedish Cancer Society (grant agreement
#160718 and #160762), the Cancer Society of Stock-
holm (grant agreement #141433, #174303) and the
Stockholm County Council (grant agreement
#20160051) and was funded by Pierre Fabre Pharma
Norden AB through an investigator-initiated research
grant (no grant number applicable). The Pierre Fabre
company had no influence on the design or performance
of the trial, and was not involved in the reporting or
interpretation of the data.
Acknowledgements
The authors thank the patients who participated in
this trial and their families. The authors are also grateful
to all investigators and the study teams at the partici-
pating centres. The authors thank the Clinical Trial Unit
at Karolinska University Hospital, especially Anita
Björk as study monitor and Claudia Maes for coordi-
nating data management.Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2019.08.033.References
[1] Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N,
Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and
cisplatin for advanced transitional cell carcinoma of the urothe-
lium. Efficacy and patterns of response and relapse. Cancer 1989;
64:2448e58.
[2] Sternberg CN, de Mulder PH, Schornagel JH, Theodore C,
Fossa SD, van Oosterom AT, et al. Randomized phase III trial of
high-dose-intensity methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) chemotherapy and recombinant human gran-
ulocyte colony-stimulating factor versus classic MVAC in
advanced urothelial tract tumors: european Organization for
Research and Treatment of Cancer Protocol no. 30924. J Clin
Oncol : Off j Am Soc Clin Oncol 2001;19:2638e46.
[3] von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T,
Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol : Off j Am Soc Clin
Oncol 2000;18:3068e77.
[4] Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T,
Oh WK, et al. Treatment of patients with metastatic urothelial
cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol :
Off j Am Soc Clin Oncol 2011;29:2432e8.
[5] De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M,
Maroto P, et al. Randomized phase II/III trial assessing gemci-
tabine/carboplatin and methotrexate/carboplatin/vinblastine in
patients with advanced urothelial cancer who are unfit for
cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol
: Off j Am Soc Clin Oncol 2012;30:191e9.
[6] De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M,
Maroto P, et al. Randomized phase II/III trial assessing gemci-
tabine/carboplatin and methotrexate/carboplatin/vinblastine in
patients with advanced urothelial cancer "unfit" for cisplatin-
based chemotherapy: phase II–results of EORTC study 30986. J
Clin Oncol : Off j Am Soc Clin Oncol 2009;27:5634e9.
[7] EAU guidelines muscle-invasive and metastatic bladder cancer.
Available at: www.uroweb.org/guideline/bladder-cancer-muscle-
invasive-and-metastatic, . [Accessed 14 April 2019].
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